Last Modified: July 6, 2003
Conference Dates: October 9-11, 2003
Conference Location: Amsterdam, The Netherlands
Sponsoring Group: Imedex. Under the auspices of EORTC
Conference Web Page URL: www.imedex.com/announcements/emelanoma03.html
Topics Covered: EORTC Melanoma Group Program Scientific Reports, Phase III Trials in Stage IV Melanoma, Vaccine Development in Melanoma, What Next: New Drugs in First Line in Stage IV Melanoma, Genetic Epidemiology, Sentinel Node and Other Prognostic Factors, Adjuvant Therapy of Melanoma Interferons, Vaccines
Conference Objectives: The objective of this meeting is to present and evaluate the most recent developments in the management of melanoma. The presentations and discussions will focus on adjuvant chemotherapy, vaccine development, genetic epidemiology, the role of sentinel node and other prognostic factors in melanoma.
Who Should Attend: This educational program is intended for oncologists, dermatologists, and other physicians in active clinical practice interested and/or involved in the management of melanoma. No specific knowledge or skills other than a general familiarity with medical oncology and/or dermatology for successful participation in this program.
Registration Information: Online at www.imedex.com ; call Imedex at +1 (770) 751 7332 or fax to +1 770-751-7334
Conference Fees: Early (by June 30) ? 299, Regular (by September 29) ? 399, Full (after September 29 and onsite) ? 499. EORTC Member discount ? 100, ESMO Member discount ? 50.
Continuing Education: Yes
Miscellany: submitted to ESMO for accreditation. Participants will receive a certificate of attendance at the end of the conference.
Feb 14, 2014 - Sentinel-node biopsy-based management of primary cutaneous melanomas is associated with improved long-term outcomes, according to a study published in the Feb. 13 issue of the New England Journal of Medicine.